Last reviewed · How we verify
Cisplatin-based induction chemotherapy
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells.
Cisplatin is a platinum-based chemotherapy agent that forms DNA crosslinks, preventing DNA replication and transcription in cancer cells. Used for Induction chemotherapy for locally advanced head and neck cancer, Induction chemotherapy for advanced ovarian cancer, Induction chemotherapy for advanced bladder cancer.
At a glance
| Generic name | Cisplatin-based induction chemotherapy |
|---|---|
| Sponsor | Ming-Yuan Chen |
| Drug class | Platinum-based alkylating agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin binds to DNA and forms intrastrand and interstrand crosslinks, which inhibit DNA synthesis and repair mechanisms, leading to apoptosis in rapidly dividing cancer cells. As an induction chemotherapy, it is typically administered before definitive treatment (such as surgery or radiation) to reduce tumor burden and improve treatment outcomes.
Approved indications
- Induction chemotherapy for locally advanced head and neck cancer
- Induction chemotherapy for advanced ovarian cancer
- Induction chemotherapy for advanced bladder cancer
- Induction chemotherapy for other solid tumors
Common side effects
- Nephrotoxicity
- Ototoxicity
- Nausea and vomiting
- Myelosuppression
- Peripheral neuropathy
- Electrolyte abnormalities (hypomagnesemia, hypokalemia)
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- A Multicenter Prospective Study Evaluating Concurrent Chemoradiotherapy Following Induction Immunochemotherapy for Esophageal Cancer Based on Dynamic ctDNA Monitoring (NA)
- Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma (PHASE2)
- Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (PHASE2)
- Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity (PHASE2)
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (PHASE3)
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma (PHASE3)
- Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cisplatin-based induction chemotherapy CI brief — competitive landscape report
- Cisplatin-based induction chemotherapy updates RSS · CI watch RSS
- Ming-Yuan Chen portfolio CI